Alcohol Consumption Emerges as a Key Risk Factor for Buccal Cancer in India
December 24, 2025
Brand Name :
Mestinon
(United States) [Available] ,Regonol
(United States) [Available]Synonyms :
Class :
Acetylcholinesterase and reversible anticholinesterases
Dosage Forms & Strengths
Solution-Oral
60 mg/5 ml
Tablet-Oral
30 mg, 60 mg
Tablet ER
180 mg
600
mg
Tablet
Orally
once a day
or 180-540 mg tablet ER orally once a day
600
mg
Tablet
Orally
once a day
or 180-540 mg tablet ER orally once a day
Reversal Of Nondepolarizing Muscle Relaxants
0.1 - 0.25
mg/kg
Orally
once a day
for full recovery 10-20 mg is very effective
To prevent side effects a dose of 0.6-1.2 mg IV atropine sulfate given immediately before pyridostigmine
Reversal Of Nondepolarizing Muscle Relaxants
0.1 - 0.25
mg/kg
Orally
once a day
for full recovery 10-20 mg is very effective
To prevent side effects a dose of 0.6-1.2 mg IV atropine sulfate given immediately before pyridostigmine
30
mg
Tablet
Orally
3 times a day
initial starting at several hours before to exposure
Dosage Forms & Strengths
Solution-Oral
60 mg/5 ml
Tablet-Oral
30 mg, 60 mg
Tablet ER
180 mg
Age: children
7 mg/kg tablet orally 4 times a day
0.05-0.15 mg/kg solution IV/IM 4times a day
Age: Newborn:
5 mg tablet orally 4times a day
0.05-0.15 mg/kg IV/IM 4 times a day
Reversal Of Nondepolarizing Muscle Relaxants
0.1 - o.2
mg/kg
Intravenous (IV)
once a day
for full recovery 0.1-0.25 mg/kg/dose is very effective
Reversal Of Nondepolarizing Muscle Relaxants
0.1 - o.2
mg/kg
Intravenous (IV)
once a day
for full recovery 0.1-0.25 mg/kg/dose is very effective
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
It may enhance the risk of adverse effects when combined with anticholinesterases
May diminish the therapeutic effect of Anticholinergic Agents
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may decrease the therapeutic effect of Acetylcholinesterase Inhibitors
It may enhance the risk of adverse effects when combined with hormone antagonists
When pyridostigmine is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
Adverse drug reactions:
Frequency Not Defined
ECG changes
Loss of consciousness
Convulsions
Drowsiness
Thrombophlebitis
Urticaria
Hypotension
Arrhythmia
Laryngospasm
Bradycardia
Pregnancy warnings:
Pregnancy Category: B
Breastfeeding warnings:
The release of the drug into the human breastmilk is unknown
Pregnancy Categories:
Patient Information Leaflet
Generic Name: pyridostigmine
Pronounciation: py-rid-o-STIG-meen
Why do we use pyridostigmine?
pyridostigmine belongs to the class Cholinergic muscle stimulants used to treat myasthenia gravis and helps in reversal of nondepolarizing muscle relaxants